Ticarcillin/Clavulanate

Brand Discontinued in U.S

General

  • Type: Anti-Pseudomonal Penicillin
  • Dosage Forms:
  • Common Trade Names: Timentin

Adult Dosing

Ticarcillin/clavulanate: each 3.1g dose contains 3g ticarcillin and 0.1g clavulanate (dosages written by ticarcillin component)

General

  • <60 kg
    • 200-300mg ticarcillin/kg/day IV divided q4-6 hours
    • First Dose:
    • Max: 18 g/day
  • ≥60 kg
    • 3.1 g every 4-6 hours
    • First Dose:
    • Max: 18 g/day

Pediatric Dosing

Ticarcillin/clavulanate: each 3.1g dose contains 3g ticarcillin and 0.1g clavulanate (dosages written by ticarcillin component)

General (≥3 Months)

  • <60 kg
    • 200-300mg ticarcillin/kg/day IV divided q4-6 hours
    • First Dose: 50mg tiacarcillin/kg IV x 1
    • Max: 18g/day
  • ≥60 kg
    • 3.1 g q4-6 hours
    • Max: 18g/day

Special Populations

  • Pregnancy: B
  • Lactation: Use caution
  • Renal Dosing

Considerations for hemodialysis/peritoneal dialysis and CRRT patients NOT included below

    • Adult

Loading dose: IV: 3.1 g one dose, followed by maintenance dose based on creatinine clearance:

CrCl 30-60 mL/minute: 2 g of ticarcillin component every 4 hours

CrCl 10-30 mL/minute: 2 g of ticarcillin component every 8 hours

CrCl <10 mL/minute: 2 g of ticarcillin component every 12 hours

CrCl <10 mL/minute with concomitant hepatic dysfunction: 2 g of ticarcillin component every 24 hours

    • Pediatric

No dosing adjustments in manufacturer's label, clinical recommendations include:

GFR >30 mL/minute/1.73 m2: No adjustment required.

GFR 10-29 mL/minute/1.73 m2: 50 to 75 mg ticarcillin/kg every 8 hours

GFR <10 mL/minute/1.73 m2 (without concomitant hepatic failure): 50 to 75 mg ticarcillin/kg every 12 hours

GFR <10 mL/minute/1.73 m2 (with concomitant hepatic failure): 50 to 75 mg ticarcillin/kg every 24 hours

  • Hepatic Dosing
    • Adult

With concomitant renal dysfunction (Clcr <10 mL/minute): 2 g of ticarcillin component every 24 hours.

    • Pediatric

No specific pediatric recommendations, adjust if concomitant renal dysfunction

Contraindications

  • Allergy to class/drug

Adverse Reactions

Serious

Common

Pharmacology

  • Half-life: Ticarcillin: 1.1 hours; Clavulanic acid: 1.1 hours
  • Metabolism:
  • Excretion:
  • Mechanism of Action:

Antibiotic Sensitivities[1]

Group Organism Sensitivity
Gram PositiveStrep. Group A, B, C, GS
Strep. PneumoniaeS
Viridans strepI
Strep. anginosus gpS
Enterococcus faecalisI
Enterococcus faeciumI
MSSAS
MRSAR
CA-MRSAR
Staph. EpidermidisI
C. jeikeiumR
L. monocytogenesX2
Gram NegativesN. gonorrhoeaeX2
N. meningitidisS
Moraxella catarrhalisS
H. influenzaeS
E. coliS
Klebsiella spS
E. coli/Klebsiella ESBL+R
E coli/Klebsiella KPC+R
Enterobacter sp, AmpC negS
Enterobacter sp, AmpC posS
Serratia spS
Serratia marcescensX1
Salmonella spS
Shigella spS
Proteus mirabilisS
Proteus vulgarisS
Providencia sp.S
Morganella sp.S
Citrobacter freundiiS
Citrobacter diversusS
Citrobacter sp.S
Aeromonas spS
Acinetobacter sp.I
Pseudomonas aeruginosaS
Burkholderia cepaciaX1
Stenotrophomonas maltophiliaS
Yersinia enterocoliticaS
Francisella tularensisX1
Brucella sp.X1
Legionella sp.R
Pasteurella multocidaS
Haemophilus ducreyiX1
Vibrio vulnificusX1
MiscChlamydophila spR
Mycoplasm pneumoniaeR
Rickettsia spX1
Mycobacterium aviumX1
AnaerobesActinomycesX1
Bacteroides fragilisS
Prevotella melaninogenicaS
Clostridium difficileX1
Clostridium (not difficile)S
Fusobacterium necrophorumS
Peptostreptococcus sp.S

Key

  • S susceptible/sensitive (usually)
  • I intermediate (variably susceptible/resistant)
  • R resistant (or not effective clinically)
  • S+ synergistic with cell wall antibiotics
  • U sensitive for UTI only (non systemic infection)
  • X1 no data
  • X2 active in vitro, but not used clinically
  • X3 active in vitro, but not clinically effective for Group A strep pharyngitis or infections due to E. faecalis
  • X4 active in vitro, but not clinically effective for strep pneumonia

See Also

References

  1. Sanford Guide to Antimicrobial Therapy 2014

Dowell JA, Korth-Bradley J, Milisci M, et al, "Evaluating Possible Pharmacokinetic Interactions Between Tobramycin, Piperacillin, and a Combination of Piperacillin and Tazobactam in Patients With Various Degrees of Renal Impairment," J Clin Pharmacol, 2001, 41:979-86 PMID: 11549103

This article is issued from Wikem. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.